Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980 to Filter to 2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980

---

Search results

• Journal article
  Izmi N, Kettner H, Carhart-Harris R, Kettner Het al., 2024,

  Psychological effects of psychedelics in adolescents

  , Frontiers in Child and Adolescent Psychiatry, Vol: 3, ISSN: 2813-4540

  This study aimed to investigate differences in long-term psychological effects, acute subjective effects, and side effects associated with psychedelic use in adolescents (aged 16–24), compared with adults (aged 25+). Data from two observational online survey cohorts was pooled, involving adolescents (average age 20.4 ± 2.2, N = 435) and adults (average age 36.5 ± 9.7, range = 25–71, N = 654) who self-initiated a psychedelic experience and were tracked via online surveys from a pre-experience baseline to four weeks post-use. Self-reported measures of well-being were collected one week before, and two and four weeks after psychedelic use. Acute subjective drug effects, dosage and contextual variables pertaining to the setting of use were measured on the day after the session. Repeated-measures analyses of covariance, t- and z-tests, as well as exploratory correlational and regression analyses tested differences in psychological changes, acute drug effects, and side effects between the two groups. Psychological well-being significantly improved in adolescents two and four weeks following psychedelic use, with a clinically relevant mean change score of 3.3 points (95% CI: 1.1–5.5). on the Warwick-Edinburgh Mental Wellbeing Scale [F(1.8, 172.9) = 13.41, η2G = .04, p < .001], statistically indistinguishable from changes in adults. Acute subjective effects differed between the age groups; adolescents reported significantly higher challenging experiences and ego-dissolution. In adolescents, visual symptoms related to “hallucinogen persisting perceptual disorder” (HPPD) were reported at a higher prevalence than in adults (73.5% vs. 34.2%, p < .001) but were reported as distressing by only one adolescent participant. To our knowledge, this is the first prospective study to examine the psychological

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Bornemann J, Close JB, Ahmad K, Barba T, Godfrey K, Macdonald L, Erritzoe D, Nutt D, Carhart-Harris Ret al., 2024,

  Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”

  , Frontiers in Psychiatry, Vol: 15, ISSN: 1664-0640

  Background: Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best. Here, we present a protocol for a mechanistic study investigating the effects of psychedelic-assisted-therapy in a fibromyalgia population. The principal focus of this trial is the central mechanism(s) of psilocybin-therapy i.e., in the brain and on associated mental schemata, primarily captured by electroencephalography (EEG) recordings of the acute psychedelic state, plus pre and post Magnetic Resonance Imaging (MRI).Methods: Twenty participants with fibromyalgia will complete 8 study visits over 8 weeks. This will include two dosing sessions where participants will receive psilocybin at least once, with doses varying up to 25mg. Our primary outcomes are 1) Lempel-Ziv complexity (LZc) recorded acutely using EEG, and the 2) the (Brief Experiential Avoidance Questionnaire (BEAQ) measured at baseline and primary endpoint. Secondary outcomes will aim to capture broad aspects of the pain experience and related features through neuroimaging, self-report measures, behavioural paradigms, and qualitative interviews. Pain Symptomatology will be measured using the Brief Pain Inventory Interference Subscale (BPI-IS), physical and mental health-related function will be measured using the 36-Item Short Form Health Survey (SF-36). Further neurobiological investigations will include functional MRI (fMRI) and diffusion tensor imaging (changes from baseline to primary endpoint), and acute changes in pre- vs post-acute spontaneous brain activity – plus event-related potential functional plasticity markers, captured via EEG.Discussion: The results of this study will provide valuable insight into the brain mechanisms involved in the action of psilocybin-therapy for fibromyalgia with potential implications for the therapeutic actio

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Lynskey MT, Thurgur H, Athanasiou-Fragkouli A, Schlag AK, Nutt DJet al., 2024,

  Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21

  , DRUGS & AGING, Vol: 41, Pages: 521-530, ISSN: 1170-229X
  • Cite
• Journal article
  Nutt D, Crome I, Young AH, 2024,

  Is it now time to prepare psychiatry for a psychedelic future?

  , BRITISH JOURNAL OF PSYCHIATRY, ISSN: 0007-1250
  • Cite
• Journal article
  Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi Eet al., 2024,

  Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity

  , JOURNAL OF AFFECTIVE DISORDERS, Vol: 353, Pages: 60-69, ISSN: 0165-0327
  • Cite
• Journal article
  Peill J, Marguilho M, Erritzoe D, Barba T, Greenway KT, Rosas F, Timmermann C, Carhart-Harris Ret al., 2024,

  Psychedelics and the 'inner healer': Myth or mechanism?

  , JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 38, Pages: 417-424, ISSN: 0269-8811
  • Cite
• Journal article
  Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris Ret al., 2024,

  Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

  , JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 38, Pages: 458-470, ISSN: 0269-8811
  • Cite
• Journal article
  Schlag AK, Nutt DJ, Lynskey M, 2024,

  Using real world evidence to optimize care: the case of medical cannabis

  , EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, Vol: 24, Pages: 463-465, ISSN: 1473-7167
  • Cite
• Journal article
  Vohryzek J, Cabral J, Timmermann C, Atasoy S, Roseman L, Nutt DJ, Carhart-Harris RL, Deco G, Kringelbach MLet al., 2024,

  The flattening of spacetime hierarchy of the N,N-dimethyltryptamine brain state is characterized by harmonic decomposition of spacetime (HADES) framework

  , NATIONAL SCIENCE REVIEW, Vol: 11, ISSN: 2095-5138
  • Cite
• Journal article
  Thurgur H, Lynskey M, Schlag AK, Croser C, Nutt DJ, Iveson Eet al., 2024,

  Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial

  , BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Vol: 90, Pages: 1081-1093, ISSN: 0306-5251
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.